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Abstract 
Background: Persistent Polyclonal Binucleated B‑cell Lymphocytosis (PPBL) is characterized by a chronic polyclonal 
B‑cell lymphocytosis with binucleated lymphocytes and a polyclonal increase in serum immunoglobulin‑M. Cytoge‑
netic is characterized by the presence of a supernumerary isochromosome +i(3)(q10), premature chromosome 
condensation and chromosomal instability. Outcome of PPBL patients is mostly benign, but subsequent malignancies 
could occur. The aim of our study is to provide an update of clinical and cytogenetic characteristics of our large cohort 
of PPBL patients, to describe subsequent malignancies occurring during the follow‑up, and to investigate the role of 
the long arm of chromosome 3 in PPBL.
Results: We analyzed clinical, biological and cytogenetic characteristics (conventional cytogenetic analysis and 
fluorescent in situ hybridization) of 150 patients diagnosed with PPBL. We performed high‑resolution SNP arrays in 
10 PPBL patients, comparing CD19+ versus CD19− lymphoid cells. We describe the cytogenetic characteristics in 
150 PPBL patients consisting in the presence of supernumerary isochromosome +i(3)(q10) (59 %) and chromosomal 
instability (55 %). In CD19+ B‑cells, we observed recurrent copy number aberrations of 143 genes with 129 gains 
(90 %) on 3q and a common minimal amplified genomic region in the MECOM gene. After a median follow‑up of 
60 months, we observed the occurrence of 12 subsequent malignancies (12 %), 6 solid tumors and 6 Non‑Hodgkin’s 
Lymphomas, and 6 monoclonal gammopathies of undetermined significance (MGUS), requiring a long‑term clinical 
follow‑up.
Conclusions: Our clinical and cytogenetic observations lead us to hypothesize that isochromosome 3q, especially 
MECOM abnormality, could play a key role in PPBL.
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Background
Persistent Polyclonal Binucleated B-cell Lymphocytosis 
(PPBL) is characterized by a chronic, stable and asymp-
tomatic lymphocytosis with binucleated lymphocytes 
[1]. Binucleated lymphocytes are not specific for PPBL 
and can be observed in patients with multiple sclero-
sis treated by natalizumab [2] or after accidental expo-
sure to ionizing radiation. In the peripheral blood, a 
polyclonal increase of memory B cells (CD19+, CD5−, 
CD27+, IgM+, IgD+) is usually associated with a poly-
clonal increase in serum immunoglobulin-M (IgM) [3–
6]. PPBL is characterized by a recurrent supernumerary 
isochromosome +i(3)(q10), a premature chromosome 
condensation (PCC) and a chromosomal instability [3, 4]. 
PPBL evolution is benign in most cases, but non-Hodg-
kin’s lymphomas and solid tumors (pulmonary blastoma) 
were previously and rarely described [7, 8]. In this study, 
we report the follow-up and the cytogenetic characteris-
tics of a large cohort of 150 PPBL patients. We report the 
occurrence of subsequent malignancies in up to 12 % of 
patients contrasting with previous studies. Strong asso-
ciation between supernumerary isochromosome 3q, 
chromosomal instability and PPBL led us to study more 
extensively the role of the long arm of chromosome 3 
using SNP arrays in 10 patients. We observed that the 
MECOM gene, located on 3q26, was recurrently ampli-
fied in B-cells of PPBL patients.
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Patients and methods
Patients
PPBL was diagnosed from the persistence during three 
months of binucleated lymphocytes on a peripheral 
blood film. Patients were included after written informed 
consent, in accordance with the Declaration of Helsinki 
and with institutional guidelines and after approval of the 
French relevant competent authorities and ethics com-
mittees (Committee of Protection of Individuals (CPP), 
Advisory Committee on the Processing of Information 
for Medical Research (CCTIRS) and the French National 
Commission for Data Protection (CNIL)).
Using multiparameter flow cytometry (MFC), B-cells 
were polyclonal in all cases, based on the expression of 
CD19 and the absence of a restriction of expression 
of light chain of immunoglobulin. Blood smears were 
reviewed in the same laboratory.
Conventional cytogenetic analysis (CCA)
Blood samples were collected on heparin tubes at the 
time of diagnosis and during the follow-up. All sam-
ples were processed in the same laboratory. CCA was 
performed as previously described [3]. As previously 
described [9], chromosomal instability was defined as the 
gain and/or loss of whole chromosomes or chromosomal 
segments at a higher rate in tumor cell population com-
pared to normal cells.
Fluorescent in situ hybridization (FISH)
FISH was performed in order to detect supernumerary 
isochromosome +i(3)(q10) in metaphase and interphase 
cells using alpha-satellite chromosome 3 specific probes 
and Bcl6 (3q27) specific probes (Vysis™, USA). One hun-
dred metaphases and three hundred interphases cells 
were analyzed per patient.
SNP array
SNP arrays were performed using Affymetrix™ Cytoge-
netics Whole-Genome 2.7M Arrays® (Affymetrix™, 
USA). All samples were processed in the same labora-
tory. Patients were selected according to the availabil-
ity of sufficient fresh cells (diagnosis) or frozen cells 
(follow-up). Immunomagnetic sorting was performed 
on whole blood samples or on thawed cells in order to 
purify CD19+ cells (Miltenyi™ AutoMACS Pro Separa-
tor®, Bergisch Gladbach, Germany). The two fractions 
(CD19+ positive and CD19− negative selection) were 
kept and the purity was checked to be >95  % by flow 
cytometry. The DNA was extracted from the two frac-
tions using Gentra Puregene Blood Kit® (Qiagen™, 
Hilden, Germany). Hybridization of the DNA on chips 
was performed according the manufacturer’s instruc-
tions. Chips were analyzed using Affymetrix™ Chro-
mosome Analysis Suite® (ChASver 1.0.1). Database 
of annotations was NetAffx Build 30. Quality con-
trols of the chips were set up according Affymetrix™ 
recommendations (SNP-QC  ≥  1.1 and MAPD (CN-
QC)  ≤  0.27). Copy Number Aberrations (CNA) were 
called according user-defined thresholds (Copy Num-
ber (CN) markers >50 and size >25 kb). The Database 
of Genomic Variants (DGV, http://projects.tcag.ca/
variation/) was consulted to determine whether CNA 
corresponded to genomic variants. Number and size 
of Copy Number Aberrations (CNAs) were analyzed 
and compared between patients and between CD19+ 
and CD19− cells. CNA are called recurrent when at 
least two patients present the same CNA. Mosaicism 
phenomenon was detected in case of allele frequencies 
between disomic and trisomic states.
Results
PPBL was diagnosed in 150 untreated patients, whose 
main characteristics are described in Table  1. Sixty-
nine percent of cases showed an absolute lymphocyto-
sis >4  ×  109/L, with a mean percentage of binucleated 
lymphocytes at 3.9  % (1–40). Median follow-up was 
60 months (1–402) and median overall survival was not 
reached. Eighteen patients (12 %) developed subsequent 
malignancies, among which nine cases were previously 
described (non Hodgkin’s lymphomas (NHL) in three 
cases, solid tumors in two cases and monoclonal gam-
mopathies of undetermined significance (MGUS) in 4 
cases) [10]. Among the 18 patients, six patients devel-
oped solid tumors with a mean time of occurrence of 
87 months (3–156) (4 pulmonary cancers, 1 breast cancer 
and 1 cervical carcinoma). Twelve patients (8  %) devel-
oped hematological malignancies. Six cases of MGUS 
(IgM) (4 %) and NHL (4 %) occurred with a mean time 
of 75  months (0–264) and 58  months (0–120), respec-
tively. Four patients developed a diffuse large B-cell lym-
phoma and 2 patients a splenic marginal zone lymphoma 
(Table  2 for details). Among these 18 cases, 17 patients 
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were chronic smokers. These data strongly lead us to 
consider PPBL as a premalignant state requiring a long-
term follow-up.
At diagnosis, CCA and FISH were performed in 140 
and 128 patients, respectively. During the follow-up, 
CCA was performed in 32 patients (21  %). CCA and 
FISH detected no cytogenetic abnormality in 52/140 
patients (37  %). Recurrent supernumerary isochromo-
some +i(3)(q10) was identified in 82/140 patients (59 %). 
PCC, arising from asynchronous mitotic activity in 
multinucleated cells, was observed concomitantly with 
+i(3)(q10) in 30/140 patients (21  %). By CCA, trisomy 
8 and del(6q) were also detected either as recurrent 
abnormalities (2/140 and 5/140, respectively) or as non-
recurrent abnormalities (9/140 and 4/140, respectively). 
Chromosomal instability was observed in 76/140 
patients (54  %) and persisted in 31/32 patients (97  %) 
during follow-up.
To determine whether 3q could be implicated in 
PPBL pathogenesis, SNP arrays were performed in 10 
patients (3 males, 7 females) with +i(3)(q10) in 9/10 
patients (Table  3 for details). Written informed con-
sents were obtained from the patients. The compara-
tive analysis of sorted CD19+ and CD19− cells revealed 
that CNAs were observed predominantly in CD19+ 
B-cells on 3q (Table 4) with mosaicism phenomenon in 
3 patients. Genetic instability was observed in all cases 
and predominantly in CD19+ B-cells. We observed 
143 recurrent CNAs with 129 gains (90  %) on 3q of 
B-cells (Table 5). Interestingly, we identified with a high 
Table 1 Characteristics and follow-up of 150 patients with PPBL
Clinical and biological data were collected from 27 centers. Median follow-up was 60 months (1–402) with unreached median overall survival
MGUS monoclonal gammopathy of undetermined significance
Age (years), Mean (min–max) 40 (18.9–66.2)
Sex (M/F) 26 (17 %)/124 (83 %)
Tobacco consumption 130/145 (90 %)
Clinical presentation
 Lymph node(s) 10/108 (9 %)
 Splenomegaly 19/106 (18 %)
 Hepatomegaly 2/108 (2 %)
Hemogram, Mean (min–max)
 White blood cells (109/L) 12.8 (7–44.8)
 Hemoglobin (g/dL) 13.8 (10.1–16.9)
 Platelets (109/L) 228 (83–380)
 Lymphocytosis (109/L) 6.5 (2.2–41)
 Binucleated Lymphocytes (% of lymphocytes) 3.9 (1–40)
IgM (g/L), Mean (min–max) 7.8 (2.17–20)
HLA DR7 positive 40/52 (77 %)
Multiparameter Flow Cytometry—Mean (min–max)
 CD19 (%) 50.4 (7–83)
Cytogenetics Diagnosis Follow‑up
 +i(3)(q10) positive by karyotype 50/140 (36 %) 20/32 (63 %)
 +i(3)(q10) positive by FISH 80/128 (63 %) 24/26 (92 %)
 PCC positive 35/140 (25 %) 8/32 (25 %)
 Chromosomal instability 76/140 (54 %) 31/32 (97 %)
Subsequent Malignancies 18/150 (12 %)
 MGUS 6/150 (4 %)
 Non‑Hodgkin’s Lymphomas 6/150 (4 %)
 Solid tumors 6/150 (4 %)
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frequency (7/9 patients) partial or complete amplifica-
tion of one particular genomic region located in 3q26.2. 
The size of this common minimal amplified region was 
28 kilobases (85 copy number markers) located in coding 
region of MECOM gene (Fig. 1). This amplification was 
not detected in two patients (UPN147 and UPN136). In 
Table 2 Eighteen subsequent malignancies occurred in PPBL patients
Six patients developed solid tumors (4 pulmonary cancers, 1 breast cancer and 1 cervical carcinoma) and 6 patients hematological malignancies (diffuse large B-cell 
lymphoma (DLBCL) in 4 cases, splenic marginal zone lymphoma (SMZL) in 2 cases) and 6 patients monoclonal gammopathies of undetermined significance (MGUS) 
(IgM)
Patients Delay between PPBL and subsequent malignancy’s diagnosis Type of malignancy Follow-up
UPN36 38 months DLBCL 56 months
UPN47 20 months SMZL +65 months
UPN57 92 months DLBCL 99 months
UPN63 Diagnosis of PPBL and lymphoma was concomitant DLBCL +13 months
UPN71 77 months SMZL +86 months
UPN83 120 months DLBCL +131 months
UPN1 264 months MGUS +348 months
UPN10 144 months MGUS +148 months
UPN157 44 months MGUS +47 months
UPN118 Diagnosis of PPBL and MGUS was concomitant MGUS +36 months
UPN163 Diagnosis of PPBL and MGUS was concomitant MGUS +57 months
UPN105 Diagnosis of PPBL and MGUS was concomitant MGUS +42 months
UPN5 96 months Mammary carcinoma +272 months
UPN6 3 months Pulmonary carcinoma 3 months
UPN70 22 months Pulmonary carcinoma +22 months
UPN86 132 months Pulmonary carcinoma +146 months
UPN160 114 months Pulmonary carcinoma 112 months
UPN67 156 months Cervical carcinoma +181 months
Table 3 Characteristics of the 10 patients analyzed by SNP arrays (UPN: Unique Patient Number)
Depending on the quality of extracted DNA, we performed DNA arrays on a both CD19+ and CD19− cells in 7 patients, bCD19+ cells in 2 patients and cCD19− cells in 1 
patient. CCA and/or FISH detected +i(3)(q10) in 9/10 patients
PCC premature chromosome condensation
Patient Karyotype PCC (%) FISH +i(3)(q10) (%)
UPN8b 46–47,XX, +i(3)(q10) [3] /46,XX,del(2)(q22), −17, +mar [1] /45, X, −X [1] /46,XX [40] Absent Present (6 %)
UPN57a 47,XY, +i(3)(q10) [5] /48,XY, +i(3)(q10), +12 [01]/46,XY,t(14;18)(q32;q22)[01]/47,XY,t(11;14)(q13;q32), 
+mar [01]/46,XY,add(3)(p26) [1] /47,XY, +22[01]/49,XY, +i(3)(q10), +8, +mar[01]/46,XY [39]
Absent Present (7 %)
UPN136a 46,XX [48]/PCC [2] Present (4 %) Present (4 %)
UPN71c 47,XX, +X,del(6)(q15q26)[01]/46,XX,del(6)(q15q26),der(6)t(6;6)(q21;q23)[08]/46,XX,del(1)(q12),der(14)
t(1;14)(p22;q32)[02]/46,XX[09]
Absent Present (2 %)
UPN127b 47,XY, +i(3)(q10) [3] /46,X,der(Y)t(Y;?)(q12;?) [3] /46,XY [12] Absent Present (12 %)
UPN138a 46,XX,del(6)(q21q24) [6] /46,XX,der(8)t(3;8)(q11;q11),der(17)t(17;?)(p11;?) [2] /46,XX,del(17)(p11) [2] 
/46,XX,t(1;6)(q24;q21) [1] /46,XX,der(14)t(14;?)(p25;?) [1] /46,XX,dup(3)(p13p26) [1] /46,XX,der(4)t(4;?)
(p16;?) [1] /46,XX [26]
Absent Present (11 %)
UPN99a 47,XX, +18 [2] /47,XX, +3 [1] /46,XX [37]/PCC [1] Present (2 %) Present (4 %)
UPN147a 46,XX [50] Absent Absent
UPN73a 46,XX [50] Absent Present (1.4 %)
UPN105a 46,XY [46]/46,XY [cp 4] Absent Present (3 %)
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Table 4 Repartition of CNAs observed in CD19− and CD19+ cells. CD19+ cells presented twice as many CNAs as CD19− [83 
CNAs (12–218) versus 42 (3–184)]
CD19− CNAs—Total (gains/losses)
Chromosome UPN73 UPN71 UPN57 UPN136 UPN138 UPN99 UPN147 UPN105 Mean
1 2 (2/0) 0 (0/0) 4 (1/3) 1 (0/1) 3 (3/0) 1 (0/1) 0 (0/0) 17 (0/17) 3.5 (0.7/2.8)
2 3 (1/2) 1 (1/0) 0 (0/0) 2 (0/2) 2 (2/0) 0 (0/0) 0 (0/0) 24 (0/24) 4.0 (0.5/3.5)
3 2 (1/1) 0 (0/0) 3 (3/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 8 (1/7) 1.6 (0.6/1.0)
3p 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0.0 (0.0/0.0)
3q 2 (1/1) 0 (0/0) 3 (3/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 8 (1/7) 1.6 (0.6/1.0)
4 0 (0/0) 0 (0/0) 0 (0/0) 2 (1/1) 0 (0/0) 0 (0/0) 1 (1/0) 30 (1/29) 4.1 (0.4/3.7)
5 0 (0/0) 1 (0/1) 1 (0/1) 0 (0/0) 1 (1/0) 0 (0/0) 0 (0/0) 15 (0/15) 2.3 (0.1/2.2)
6 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (1/0) 0 (0/0) 0 (0/0) 11 (0/11) 1.5 (0.1/1.4)
7 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (1/0) 0 (0/0) 1 (1/0) 12 (0/12) 1.8 (0.3/1.5)
8 1 (0/1) 0 (0/0) 0 (0/0) 1 (1/0) 3 (3/0) 0 (0/0) 0 (0/0) 6 (0/6) 1.4 (0.5/0.9)
9 0 (0/0) 4 (0/4) 3 (0/3) 0 (0/0) 4 (2/2) 1 (1/0) 0 (0/0) 7 (0/7) 2.4 (0.4/2.0)
10 1 (1/0) 1 (0/1) 1 (0/1) 0 (0/0) 1 (1/0) 0 (0/0) 1 (1/0) 7 (0/7) 1.5 (0.4/1.1)
11 0 (0/0) 2 (1/1) 0 (0/0) 0 (0/0) 2 (2/0) 0 (0/0) 1 (0/1) 10 (0/10) 1.9 (0.4/1.5)
12 2 (2/0) 0 (0/0) 1 (0/1) 0 (0/0) 1 (1/0) 0 (0/0) 0 (0/0) 8 (1/7) 1.5 (0.5/1.0)
13 0 (0/0) 0 (0/0) 2 (0/2) 0 (0/0) 1 (0/1) 0 (0/0) 0 (0/0) 8 (1/7) 1.4 (0.1/1.3)
14 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 6 (1/5) 0.8 (0.1/0.7)
15 2 (2/0) 1 (1/0) 1 (0/1) 2 (0/2) 2 (1/1) 0 (0/0) 1 (1/0) 4 (1/3) 1.6 (0.9/0.7)
16 1 (1/0) 0 (0/0) 0 (0/0) 1 (1/0) 3 (1/2) 0 (0/0) 0 (0/0) 1 (0/1) 0.8 (0.4/0.4)
17 0 (0/0) 0 (0/0) 1 (0/1) 0 (0/0) 1 (1/0) 0 (0/0) 0 (0/0) 4 (2/2) 0.8 (0.4/0.4)
18 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (1/0) 0 (0/0) 0 (0/0) 1 (0/1) 0.2 (0.2/0.1)
19 0 (0/0) 1 (0/1) 0 (0/0) 0 (0/0) 0 (0/0) 1 (0/1) 1 (0/1) 1 (0/1) 0.5 (0.0/0.5)
20 1 (1/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (1/0) 0 (0/0) 0 (0/0) 0 (0/0) 0.3 (0.3/0.0)
21 1 (0/1) 1 (0/1) 1 (0/1) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (0/1) 0.5 (0.0/0.5)
22 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (1/0) 1 (1/0) 0.3 (0.3/0.0)
X 1 (1/0) 7 (6/1) 13 (13/0) 1 (0/1) 25 (24/1) 0 (0/0) 2 (1/1) 1 (0/1) 6.2 (5.6/0.6)
Y 1 (1/0) 1 (1/0) 2 (0/2) 0 (0/0) 2 (2/0) 0 (0/0) 0 (0/0) 1 (0/1) 0.9 (0.5/0.4)
Total 18 (13/5) 20 (10/10) 33 (18/15) 10 (3/7) 55 (48/7) 3 (1/2) 9 (6/3) 184 (9/175) 41.5 (13.5/28)
CD19+ CNAs—total (gains/losses)
Chromosome UPN73 UPN8 UPN57 UPN136 UPN127 UPN138 UPN99 UPN147 UPN105 Mean
1 20 (19/1) 0 (0/0) 0 (0/0) 4 (0/4) 0 (0/0) 0 (0/0) 5 (4/1) 8 (1/7) 0 (0/0) 5.0 (3.6/1.4)
2 22 (22/0) 2 (1/1) 0 (0/0) 2 (0/2) 0 (0/0) 1 (0/1) 3 (3/0) 12 (1/11) 0 (0/0) 5.7 (3.9/1.8)
3 20 (19/1) 4 (4/0) 26 (25/1) 0 (0/0) 46 (46/0) 1 (1/0) 2 (2/0) 5 (0/5) 113 (113/0) 25.0 (24.2/0.8)
3p 11 (11/0) 0 (0/0) 1 (0/1) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1.8 (1.7/0.1)
3q 9 (8/1) 4 (4/0) 25 (25/0) 0 (0/0) 46 (46/0) 1 (1/0) 2 (2/0) 5 (0/5) 113 (113/0) 23.2 (22.6/0.7)
4 9 (9/0) 0 (0/0) 2 (0/2) 5 (1/4) 0 (0/0) 1 (1/0) 0 (0/0) 10 (1/9) 0 (0/0) 4.0 (2.3/1.7)
5 14 (13/1) 0 (0/0) 0 (0/0) 2 (0/2) 0 (0/0) 0 (0/0) 0 (0/0) 5 (0/5) 1 (0/1) 3.4 (2.4/1.0)
6 10 (10/0) 1 (1/0) 0 (0/0) 1 (0/1) 0 (0/0) 1 (1/0) 1 (1/0) 5 (1/4) 0 (0/0) 2.9 (2.3/0.6)
7 12 (12/0) 1 (0/1) 0 (0/0) 1 (0/1) 1 (0/1) 0 (0/0) 1 (1/0) 6 (1/5) 0 (0/0) 2.4 (1.6/0.8)
8 13 (11/2) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (0/1) 1 (1/0) 2 (0/2) 0 (0/0) 2.3 (1.8/0.5)
9 14 (14/0) 0 (0/0) 0 (0/0) 4 (0/4) 0 (0/0) 5 (0/5) 1 (1/0) 4 (1/3) 0 (0/0) 3.8 (2.4/1.4)
10 8 (8/0) 0 (0/0) 0 (0/0) 3 (0/3) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1.6 (1.2/0.4)
11 9 (9/0) 0 (0/0) 0 (0/0) 2 (0/2) 0 (0/0) 0 (0/0) 1 (1/0) 7 (0/7) 0 (0/0) 2.8 (1.8/1.0)
12 5 (5/0) 1 (0/1) 2 (0/2) 0 (0/0) 1 (1/0) 0 (0/0) 1 (1/0) 8 (1/7) 0 (0/0) 2.7 (1.6/1.1)
13 4 (4/0) 0 (0/0) 1 (0/1) 2 (0/2) 0 (0/0) 1 (0/1) 0 (0/0) 2 (0/2) 1 (1/0) 1.3 (0.7/0.6)
14 3 (3/0) 0 (0/0) 1 (0/1) 0 (0/0) 0 (0/0) 0 (0/0) 2 (2/0) 0 (0/0) 0 (0/0) 1.1 (1.0/0.1)
15 5 (5/0) 0 (0/0) 1 (1/0) 1 (0/1) 2 (0/2) 1 (0/1) 0 (0/0) 2 (1/1) 1 (1/0) 1.8 (1.2/0.6)
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one of them (UPN147), no +i(3)(q10) was detected by 
CCA and/or FISH. Unfortunately, due to the mosaicism 
phenomenon, with less than 20  % of B-cells presenting 
+i(3)(q10), gain in MECOM gene has not been con-
firmed yet by other molecular studies, such as quantita-
tive PCR.
Discussion
Similar to the described link between aneuploidy, 
genetic instability and the development of human can-
cers [11, 12], supernumerary isochromosome 3q could 
be the cause of chromosomal instability observed in 
PPBL. Transfer of isochromosome 3q into myoblast cell 
line caused abnormal cytokinesis, centrosome ampli-
fication, aneuploidy and abolished G1 arrest follow-
ing DNA damage. These observations might be related 
to an increasing expression of ATR gene located on 3q 
[13]. Moreover, isochromosome 3q has been impli-
cated in the progression of cervical carcinomas, where 
cells exhibiting either tetrasomy or aneusomy for chro-
mosomes 3 and 17 increased significantly with disease 
progression [13–16]. Supernumerary isochromosome 
3q could explain binucleated lymphocytes and chromo-
somal instability observed in PPBL. MECOM abnor-
malities, particularly the overexpression of EVI1, have 
been described in the pathogenesis of myeloid neoplasm 
such as acute myeloid leukemia and myelodysplastic 
syndrome, especially concerning cell-cycle disorders 
[17–21]. Furthermore, as observed by Stein et al., EVI1 
activation could lead to genetic instability [22]. Even if 
it has never been observed in lymphoid neoplasm, the 
potential implication of MECOM in PPBL has to be 
elucidated.
The link between PPBL and subsequent malignan-
cies remains unclear and the role of tobacco is prob-
ably dominant. Majority of our patients (17/18) with 
subsequent malignancies were chronic smokers. We 
reported recently a detailed description of 2 heavy smok-
ers patients with subsequent malignancies, UPN57 and 
UPN71 [23]. Tobacco use is a recognized risk factor in 
the development of solid tumor, such as pulmonary can-
cer, and also lymphoma [24]. Therefore, in PPBL, where 
tobacco consumption is frequent (90 % of our cohort of 
150 patients), smoking could represent a confounding 
factor in interpreting the link between PPBL and subse-
quent malignancies.
Isochromosome 3q has been described in cell-cycle 
deregulation, chromosomal instability and progression 
of cervical cancers. Our cytogenetic and clinical observa-
tions lead us to hypothesize that isochromosome 3q in 
B-cells plays a key role in the physiopathology and evolu-
tion of PPBL. Although isochromosome 3q has not been 
yet identified in tumor cells of subsequent malignancies 
[23], it could be implicated in chromosomal and genomic 
instability. This genomic instability could be part of a multi-
step process leading to the emergence of a malignant B 
28 % of CNAs (0–97 %) were located on 3q in CD19+  cells compared to 5 % (0–11 %) in CD19− cells (data not shown)
Table 4 continued
CD19+ CNAs—total (gains/losses)
Chromosome UPN73 UPN8 UPN57 UPN136 UPN127 UPN138 UPN99 UPN147 UPN105 Mean
16 2 (2/0) 0 (0/0) 0 (0/0) 2 (0/2) 1 (1/0) 2 (0/2) 0 (0/0) 1 (1/0) 1 (0/1) 1.6 (1.0/0.6)
17 4 (4/0) 0 (0/0) 0 (0/0) 1 (0/1) 1 (1/0) 0 (0/0) 0 (0/0) 1 (1/0) 0 (0/0) 0.9 (0.8/0.1)
18 5 (5/0) 1 (1/0) 0 (0/0) 0 (0/0) 0 (0/0) 3 (3/0) 1 (1/0) 1 (0/1) 0 (0/0) 1.9 (1.8/0.1)
19 1 (1/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (0/1) 0 (0/0) 0 (0/0) 1 (0/1) 0 (0/0) 0.4 (0.2/0.2)
20 5 (5/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 2 (2/0) 1 (1/0) 0 (0/0) 1.2 (1.2/0.0)
21 1 (0/1) 0 (0/0) 0 (0/0) 1 (0/1) 0 (0/0) 1 (0/1) 0 (0/0) 2 (0/2) 0 (0/0) 0.6 (0.0/0.6)
22 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 0 (0/0) 1 (1/0) 0 (0/0) 0.3 (0.3/0.0)
X 28 (27/1) 1 (0/1) 1 (1/0) 7 (5/2) 2 (2/0) 5 (4/1) 1 (1/0) 5 (3/2) 0 (0/0) 7.0 (6.2/0.2)
Y 4 (4/0) 1 (1/0) 0 (0/0) 6 (6/0) 0 (0/0) 14 (14/0) 2 (2/0) 0 (0/0) 0 (0/0) 3.0 (3.0/0.0)
Total 218 (211/7) 12 (8/4) 34 (27/7) 44 (12/32) 55 (51/4) 37 (24/13) 24 (23/1) 89 (15/74) 117 (115/2) 82.7 
(66.6/16.1)
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Table 5 Recurrent Copy Number Aberrations (CNA) in CD19+ B-cells. 143 CNA had been observed
Chr Cytoregion Recurrence Recurrence 
including 
mosaicism









1 p33 2 2 Loss FAF1 31 I No
1 p32.2 2 2 Gain C1orf168 50.2 E/I No
2 p23.2 2 2 Gain ALK 62 E/I Yes
2 q21.2–q21.3 2 2 Gain MGAT5 72 E/I No
3 p24.2 2 2 Gain THRB 55.7 I No
3 q11.2 2 3 Gain LOC255025 50 E/I No
3 q12.2 2 3 Gain ABI3BP 143 E/I Yes
3 q13.13 2 3 Gain DZIP3 10.6 I No
3 q13.31 2 3 Gain ZBTB20 39 I No
3 q13.31 2 3 Gain GAP43 399 T No
3 q13.31 2 3 Gain LSAMP 53 I No
3 q13.33 2 3 Gain TMEM39A 176 T No
3 q13.33 2 3 Gain KTELC1 176 T No
3 q13.33 2 3 Gain C3orf1 176 T No
3 q13.33 2 3 Gain CD80 176 T No
3 q13.33 2 3 Gain ADPRH 176 T No
3 q21.1 2 3 Gain HSPBAP1 101 E/I No
3 q21.1 2 4 Gain DIRC2 101 T No
3 q21.1 2 4 Gain LOC100129550 101 T Yes
3 q21.1 2 4 Gain SEC22A 114 T No
3 q21.1 2 4 Gain PTPLB 125 T No
3 q21.1 3 4 Gain MYLK 70 E/I No
3 q21.1 2 4 Gain CCDC14 121 E/I Yes
3 q21.2 2 4 Gain KALRN 169 T No
3 q21.2 2 4 Gain UMPS 169 T No
3 q21.2 2 4 Gain ZNF148 164 E/I Yes
3 q21.2 2 4 Gain ALDH1L1 171 E/I No
3 q21.3 3 4 Gain TXNRD3IT1 299 E/I No
3 q21.3 3 4 Gain CHCHD6 299 E/I No
3 q21.3 2 4 Gain KLHDC6 95 T No
3 q21.3 2 4 Gain RUVBL1 211 E/I Yes
3 q21.3 2 4 Gain EEFSEC 211 E/I Yes
3 q21.3 2 4 Gain GATA2 76 E/I Yes
3 q21.3 3 4 Gain LOC90246 76 T Yes
3 q21.3 2 4 Gain C3orf27 120.7 T Yes
3 q21.3 2 4 Gain TMCC1 268 T No
3 q21.3 2 4 Gain COL6A4P2 131 T Yes
3 q22.1 2 4 Gain MRPL3 62 E/I Yes
3 q22.1 2 4 Gain SNORA58 62 T Yes
3 q22.1 3 5 Gain CPNE4 46 I Yes
3 q22.1 2 4 Gain CPNE4 155 E/I Yes
3 q22.1 2 4 Gain TMEM108 120 I Yes
3 q22.1 2 4 Gain TOPBP1 69 E/I No
3 q22.1 2 4 Gain RYK 225 T No
3 q22.1 2 4 Gain ANAPC13 197 T Yes
3 q22.1 2 4 Gain CEP63 197 T Yes
3 q22.2 2 4 Gain EPHB1 144 E/I No
3 q22.2 2 4 Gain PPP2R3A 85 E/I No
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Table 5 continued
Chr Cytoregion Recurrence Recurrence 
including 
mosaicism









3 q22.3 2 4 Gain SOX14 925 T No
3 q22.3 3 4 Gain CLDN18 121 T Yes
3 q22.3 2 4 Gain ARMC8 77 E/I Yes
3 q22.3 2 4 Gain TXNDC6 77 E/I Yes
3 q22.3 2 4 Gain ESYT3 202.7 E/I No
3 q22.3 2 4 Gain CEP70 202.7 T No
3 q22.3 2 4 Gain FAIM 202.7 T No
3 q22.3 2 4 Gain PIK3CB 202.7 E/I No
3 q22.3 3 4 Gain LOC729627 193 T No
3 q22.3 3 4 Gain LOC389151 193 T No
3 q22.3 3 4 Gain FLJ46210 193 T No
3 q22.3 3 4 Gain BPESC1 193 T No
3 q22.3 2 4 Gain PISRT1 319 T No
3 q23 2 4 Gain MRPS22 89 E/I No
3 q23 2 4 Gain COPB2 89 T No
3 q23 3 4 Gain NMNAT3 277.8 E/I No
3 q23 4 5 Gain CLSTN2 46 I Yes
3 q23 2 4 Gain TRIM42 443 T Yes
3 q23 2 4 Gain SLC25A36 443 T Yes
3 q24 2 4 Gain SLC9A9 138 E/I Yes
3 q24 2 4 Gain PLSCR4 47 E/I No
3 q24 2 4 Gain PLSCR5 69 T No
3 q24 2 4 Gain AGTR1 194 E/I No
3 q25.1 2 4 Gain P2RY13 74 E/I No
3 q25.1 2 4 Gain MED12L 74 E/I No
3 q25.1 2 4 Gain P2RY13 74 T No
3 q25.2 2 4 Gain SGEF 364 E/I Yes
3 q25.2–q25.31 3 4 Gain MME 87.4 E/I No
3 q25.32 2 4 Gain VEPH1 78 E/I Yes
3 q25.32 2 4 Gain C3orf55 78 E/I No
3 q25.32 3 4 Gain MLF1 50 E/I No
3 q26.1 2 4 Gain C3orf57 120.6 E/I No
3 q26.1 2 4 Gain OTOL1 120.6 T No
3 q26.1 3 4 Gain SI 747 T No
3 q26.1 3 4 Gain BCHE 329 E/I No
3 q26.1 2 4 Gain ZBBX 307 T No
3 q26.2 6 7 Gain MDS1 28 E/I No
3 q26.2 2 4 Gain TERC 59 T Yes
3 q26.2 2 4 Gain ARPM1 59 T Yes
3 q26.2 2 4 Gain MYNN 59 T Yes
3 q26.2 2 4 Gain LRRC34 59 E/I Yes
3 q26.2 3 5 Gain TNIK 31 E/I No
3 q26.31 2 4 Gain NLGN1 125 I Yes
3 q26.31 2 4 Gain NLGN1 64 E/I No
3 q26.31 2 4 Gain NAALADL2 113 E/I Yes
3 q26.32 2 4 Gain TBL1XR1 60 E/I No
3 q26.32 2 4 Gain KCNMB2 121 E/I No
3 q26.33 2 4 Gain USP13 59 E/I No
3 q26.33 2 4 Gain PEX5L 81 E/I No
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Chr Cytoregion Recurrence Recurrence 
including 
mosaicism









3 q26.33 2 4 Gain CCDC39 118 E/I Yes
3 q27.1 2 4 Gain YEATS2 112 E/I No
3 q27.1 2 4 Gain MAP6D1 112 T No
3 q27.1 2 4 Gain PARL 112 E/I No
3 q27.2 2 4 Gain VPS8 218 E/I No
3 q27.2 2 4 Gain ETV5 157 T No
3 q27.2 2 4 Gain DGKG 157 E/I No
3 q27.3 2 4 Gain CRYGS 110 E/I No
3 q27.3 2 4 Gain TBCCD1 110 T No
3 q27.3 2 4 Gain DNAJB11 110 T No
3 q27.3 2 4 Gain AHSG 110 T Yes
3 q27.3 2 4 Gain FETUB 110 E/I Yes
3 q27.3 2 4 Gain ST6GAL1 46 E/I Yes
3 q27.3 2 4 Gain MASP1 428 E/I No
3 q27.3 3 4 Gain RTP4 148 T No
3 q27.3 2 4 Gain SST 428 T No
3 q27.3 2 4 Gain FLJ42393 191 T Yes
3 q28 3 4 Gain LPP 191 E/I Yes
3 q28 2 4 Gain TP63 142 E/I No
3 q28 2 4 Gain CLDN1 203 T No
3 q28 2 4 Gain CLDN16 203 T No
3 q28 2 4 Gain TMEM207 203 T No
3 q29 2 4 Gain C3orf59 396 E/I No
3 q29 2 4 Gain MGC2889 396 T Yes
3 q29 2 4 Gain HRASLS 396 T Yes
3 q29 2 4 Gain ATP13A5 396 E/I No
3 q29 2 4 Gain ATP13A4 158 E/I Yes
3 q29 2 4 Gain OPA1 158 T Yes
3 q29 2 4 Gain GP5 97 E/I No
3 q29 2 4 Gain ATP13A3 97 T Yes
3 q29 2 4 Gain TM4SF19 87 E/I Yes
3 q29 2 4 Gain UBXN7 87 E/I Yes
3 q29 2 4 Gain DLG1 240 E/I Yes
3 q29 2 4 Gain FYTTD1 50 T Yes
3 q29 2 4 Gain LRCH3 50 E/I Yes
3 q29 2 4 Gain RPL35A 91 E/I Yes
3 q29 2 4 Gain IQCG 91 E/I Yes
3 q29 2 4 Gain LMLN 91 T Yes
4 q13.3 2 2 Gain SLC4A4 46 E/I No
11 p15.1 2 2 Gain NELL1 43 I No
14 q13.1 2 2 Gain NPAS3 43 I Yes
16 p11.1 2 2 Gain LOC283914 277 T Yes
21 p11.2–p11.1 2 3 Loss TPTE 107 T Yes
X p22.33 3 3 Gain DHRSX 31 E/I Yes
X q12 2 2 Gain EDA2R 91 E/I Yes
Y q11.21 2 2 Gain USP9Y 60 E/I No
129 gains concerned the long arm of chromosome 3 (3q). 123 gains concerned gene coding regions. 75 CNA did not include previously reported polymorphism 
(Database of Genomic Variants, DGV). Gain of one exon of MDS1 (part of MECOM gene) was recurrently observed in 7 patients (including mosaicism phenomenon)
Chr chromosome, Recurrence number of patients with the same CNA, CN state Copy Number state, gain or loss
Table 5 continued
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Persistent polyclonal B‑cell lymphocytosis is an expansion of functional 
IgD(+)CD27(+) memory B cells. Br J Haematol. 2001;114(2):400–5.
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genes in persistent polyclonal B cell lymphocytosis reveals absence 
of selection in CD27+ IgM+ IgD+ memory B cells. Eur J Immunol. 
2002;32(12):3678–88.
 7. Lawlor E, Murray M, O’Briain DS, Blaney C, Foroni L, Sarsfield P, Condell 
D, Sullivan F, McCann SR. Persistent polyclonal B lymphocytosis with 
Epstein‑Barr virus antibodies and subsequent malignant pulmonary 
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Fig. 1 Schematic representation of region 3q26.2 corresponding to MECOM gene in CD19+ B‑cells of 9 patients. We observed a common minimal 
amplified region of 28 kilobases (85 copy number markers) in 7 patients. This amplification is observed in all the CD19+ B‑cells in 6 patients (copy 
number at 3, CN 3) and in a part of CD19+ B‑cells in 1 patient (copy number between 2 and 3 revealing a mosaicism phenomenon)
lymphoproliferation. MECOM gene could be a good can-
didate to explain these observations and remains to be 
explored.
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